Amylin Symlin
Executive Summary
Pramlintide acetate (NDA 21-332) will be reviewed by the FDA Endocrinologic & Metabolic Drugs Advisory Committee as adjunctive therapy with insulin to improve glycemic and metabolic control in patients with type 1 and 2 diabetes. The committee will meet July 26 at the Holiday Inn in Bethesda, Md. at 8 a.m